VJHemOnc is committed to improving our service to you

VJVirtual | Venetoclax & AML

VJHemOnc is committed to improving our service to you

Charles Craddock

Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, University of Birmingham, Birmingham, UK, touches on the promising data seen in use of venetoclax for the treatment of acute meyloid leukemia (AML), the optimization of this treatment for different patient populations and it’s use in the post-transplant setting. Cusatuzumab and magrolimab are also discussed. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter